IOL Chemicals & Pharmaceuticals has received EU-REACH registration for its product Triacetin, a critical step enabling exports across all European Union countries.

The certification was granted under the Registration, Evaluation, Authorisation and Restriction of Chemicals framework by the European Chemicals Agency. This regulatory approval directly addresses market access barriers, allowing the company to legally distribute Triacetin within the EU region.

Regulatory details

The company filed this disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the SEBI Master Circular dated January 30, 2026. The registration is valid in accordance with the applicable provisions of the EU REACH Regulation, subject to continued compliance with regulatory requirements.

Strategic implications

This registration strengthens the company's regulatory compliance profile and enhances its access to international markets. It supports the broader corporate strategy of expanding global presence through targeted product registrations and regulatory approvals. No withdrawal, cancellation, or suspension of the license has been reported.

IOL Chemicals and Pharmaceuticals Limited will host a virtual group meeting with investors and analysts on September 28, 2026. The event is organized by Nuvama Private Client Group (PCG). This interaction provides a platform for stakeholders to engage with the company's management regarding its recent performance.

The meeting is scheduled as a group meeting in virtual mode. It is conducted pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The primary objective is to facilitate communication between the company and the investment community.

Meeting details and scope

The discussion during the conference will be strictly limited to past financial results and information already available in the public domain. The company has explicitly stated that no unpublished price-sensitive information (UPSI) will be disclosed during this session. This ensures compliance with regulatory standards regarding fair disclosure.

Regulatory compliance and notes

The schedule for the analyst and institutional investor meeting is subject to change due to unforeseen circumstances. Such changes may arise from last-minute adjustments in investor or broker participation, or cancellations. The company filed this notice with both the National Stock Exchange of India Ltd and BSE Limited on September 23, 2026.

Abhay Raj Singh, Senior Vice President and Company Secretary, signed the digital notice confirming the schedule. Stakeholders are advised to refer to official company communications for any updates regarding the event logistics.